Op0061 Jia and Work Loss in Young Adulthood: Nationwide Cohort Study

Background: Patients diagnosed with JIA during the last two decades have had access to considerably better drug treatments than previous cohorts. The level of work loss in young adulthood for the current generation of patients has not been described in large cohorts using objective measures of the outcome. Objectives: To compare trajectories of work loss in individuals with JIA versus age-sex-matched comparators from the general population. Methods: Patients with JIA (n=4749; 63.4% women) were identified in the Swedish National Patient Register (2001-2017) and individually matched to up to 5 general population comparators on birthyear, sex, and residence county (n=23,758). Compensated sick leave and disability pension data, including sick leave spells longer than 14 days, were retrieved from the Social Insurance Agency from age 18y. Mean differences were estimated using linear regression with adjustment for parental education. Results: Patients with JIA had higher mean annual work loss than their matched general population comparators during all years between 18-30 years of age (Figure 1). At age 20y, patients with JIA had a mean 24 days of work loss annually compared with 12 among comparators (adjusted mean difference 12 days, 95%CI 10-14). The corresponding work loss at age 25y was 31 vs 16 days (adjusted mean difference 15 days, 95%CI 12-18) and at age 30y, 34 vs 20 days (adjusted mean difference 14 days, 95%CI 8-19). The distribution of work loss was heavily skewed with 75% of patients with JIA and 85% of general population comparators not having any compensated work loss days at age 25y, while about 5% vs 1% had 6 months or more of compensated work loss at that age (PConclusion: JIA is associated with about twice as high annual work loss in young adulthood compared to the general population, driven by a minority of patients with extensive work loss. Until age 30y, more than 75% of patients with JIA had no work loss compensation for spells longer than 14 days in a given year. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: Gustaf Bruze Agreements between Karolinska Institutet (with JA as PI) and Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS)., Heather Miller: None declared, Johan Askling Agreements between Karolinska Institutet (with JA as PI) and Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS)., Martin Neovius Agreements between Karolinska Institutet (with JA as PI) and Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS).